NasdaqGS - Nasdaq Real Time Price USD

SOPHiA GENETICS SA (SOPH)

Compare

3.3800

-0.0500

(-1.46%)

At close: January 14 at 4:00:00 PM EST

3.2500

-0.13

(-3.85%)

After hours: 7:57:48 PM EST

3 US Penny Stocks With Market Caps Under $200M

As the U.S. stock market navigates a period of mixed performance, with tech stocks under pressure and bond yields on the rise, investors are looking for opportunities beyond the major indices. For those willing to explore smaller or newer companies, penny stocks—despite their somewhat outdated name—continue to offer intriguing possibilities. These stocks often represent affordability and growth potential, particularly when backed by solid financials.

Simply Wall St. yesterday

BDTX

SOPH
-1.46%
NVRO
US Penny Stocks To Watch In December 2024

As the U.S. stock market enters December 2024, investors are witnessing record highs for the S&P 500 and Nasdaq Composite, marking a robust period of growth following significant gains in November. Amid this backdrop, penny stocks—often associated with smaller or newer companies—remain an intriguing investment option due to their potential for substantial growth at lower price points. While traditionally considered speculative, those penny stocks with strong financials can offer unique...

Simply Wall St. last month

KRMD

SOPH
-1.46%
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and e

PR Newswire last month

SOPH
-1.46%
Earnings Release: Here's Why Analysts Cut Their SOPHiA GENETICS SA (NASDAQ:SOPH) Price Target To US$6.00

SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders are probably feeling a little disappointed, since its shares fell 5.0...

Simply Wall St. 2 months ago

SOPH
-1.46%
SOPHiA GENETICS Faces Financial Challenges Amid Losses

SOPHiA GENETICS (SOPH) has released an update. SOPHiA GENETICS reported a revenue of $15.8 million for the third quarter of 2024, slightly down from $16.3 million in the same period in 2023. Despite a gross profit of $10.7 million, the company incurred a significant operating loss of $15.4 million, largely due to high research, selling, and administrative costs. This financial performance may pose challenges for investors considering the company’s stock, as losses before income taxes amounted to

TipRanks 2 months ago

SOPH
-1.46%
SOPHiA GENETICS Third Quarter 2024 Earnings: Misses Expectations

SOPHiA GENETICS ( NASDAQ:SOPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$15.9m (down 2.8% from 3Q...

Simply Wall St. 2 months ago

SOPH
-1.46%
Sophia Genetics SA (SOPH) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...

Sophia Genetics SA (SOPH) reports a mixed quarter with improved operational efficiency and strategic advancements amid revenue challenges.

GuruFocus.com 2 months ago

SOPH
-1.46%
Q3 2024 Sophia Genetics SA Earnings Call

Q3 2024 Sophia Genetics SA Earnings Call

Thomson Reuters StreetEvents 2 months ago

SOPH
-1.46%
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO.

PR Newswire 2 months ago

SOPH
-1.46%
SOPHiA GENETICS Reports Third Quarter 2024 Results

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024.

PR Newswire 2 months ago

SOPH
-1.46%
SOPHiA GENETICS SA (SOPH): A Bull Case Theory

We came across a bullish thesis on SOPHiA GENETICS SA (SOPH) on Two Natural Cap’s Substack by Two Natural Capital. In this article, we will summarize the bulls’ thesis on SOPH. SOPHiA GENETICS SA (SOPH)’s share was trading at $3.64 as of Nov 1st. Sophia Genetics is carving out a unique niche in the crowded cancer screening […]

Insider Monkey 2 months ago

SOPH
-1.46%
Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?

Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

FLGT

SOPH
-1.46%
US Penny Stocks To Watch In October 2024

As the U.S. stock market gears up for a significant week of earnings and economic data releases, major indices like the Dow Jones, S&P 500, and Nasdaq are showing positive momentum. Amidst this backdrop, investors often look beyond the large-cap stocks to explore opportunities in smaller companies that may offer unique growth prospects. Although penny stocks may seem like a relic from earlier trading days, they continue to represent an intriguing area for investment by highlighting companies...

Simply Wall St. 2 months ago

SOPH
-1.46%
REFR

TELA
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

PR Newswire 2 months ago

SOPH
-1.46%
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.

PR Newswire 3 months ago

SOPH
-1.46%
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

PR Newswire 4 months ago

SOPH
-1.46%
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutions to fuel the next wave of innovation in oncology by making real-world data available for research.

PR Newswire 4 months ago

SOPH
-1.46%
Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout

Under the collaboration, AstraZeneca will support the rollout of MSK-ACCESS to 20 global locations over the next 12 months.

Medical Device Network 4 months ago

SOPH
-1.46%
AZN
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.

PR Newswire 4 months ago

SOPH
-1.46%
AZN

AZNCF
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio's extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to identify patients with ecDNA amplified tumors using the SOPHiA DDM™ Platform. The two companies collaborated with

PR Newswire 4 months ago

SOPH
-1.46%

Performance Overview

Return	SOPH	S&P 500
YTD	+8.86%	-1.08%
1-Year	-35.37%	+22.14%
3-Year	-78.33%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SOPHiA GENETICS SA (SOPH)

3 US Penny Stocks With Market Caps Under $200M

US Penny Stocks To Watch In December 2024

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

Earnings Release: Here's Why Analysts Cut Their SOPHiA GENETICS SA (NASDAQ:SOPH) Price Target To US$6.00

SOPHiA GENETICS Faces Financial Challenges Amid Losses

SOPHiA GENETICS Third Quarter 2024 Earnings: Misses Expectations

Sophia Genetics SA (SOPH) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...

Q3 2024 Sophia Genetics SA Earnings Call

SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

SOPHiA GENETICS Reports Third Quarter 2024 Results

SOPHiA GENETICS SA (SOPH): A Bull Case Theory

Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?

US Penny Stocks To Watch In October 2024

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

Performance Overview